KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Change in Accured Expenses (2017 - 2025)

Cardlytics (CDLX) has disclosed Change in Accured Expenses for 9 consecutive years, with -$2.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 27.98% year-over-year to -$2.5 million, compared with a TTM value of -$724000.0 through Dec 2025, up 89.1%, and an annual FY2025 reading of -$724000.0, up 89.1% over the prior year.
  • Change in Accured Expenses was -$2.5 million for Q4 2025 at Cardlytics, down from $842000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.8 million in Q2 2022 and bottomed at -$11.6 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$1.3 million, with a median of $168500.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses crashed 9211.76% in 2021, then soared 1627.27% in 2023.
  • Year by year, Change in Accured Expenses stood at $1.7 million in 2021, then crashed by 315.11% to -$3.7 million in 2022, then surged by 175.36% to $2.8 million in 2023, then tumbled by 223.73% to -$3.5 million in 2024, then increased by 27.98% to -$2.5 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CDLX at -$2.5 million in Q4 2025, $842000.0 in Q3 2025, and -$975000.0 in Q2 2025.